There is an odd number at the center of Capwell Communications. It is not an impression count or a valuation. It is seven. The public-relations firm says it will carry no more than seven client partnerships at one time. In an industry that tends to advertise scale with head counts, office maps and logo walls, Capwell advertises an empty chair - the one it refuses to fill.
The constraint makes more sense when you look at the work. Capwell specializes in venture-backed life-sciences and consumer-wellness companies. A client may arrive with a promising device, a dense clinical paper and a vocabulary that works beautifully inside a laboratory. The people it must persuade are elsewhere: investors, clinicians, regulators, reporters, strategic buyers and patients. These groups do not share a language, a timetable or even the same definition of proof.
Capwell's job is to build the bridge. It develops positioning and key messages, handles earned and social media, plans FDA-approval communications, manages reputation and crisis response, and produces digital content, infographics and video. The unit of value is not the press release. It is sustained understanding across the years between an early raise and a possible acquisition or public offering.
The sentence before the story
Kimberly Capwell, the firm's founder and chief strategist, once explained her method in a PRWeek session. Start by talking to a few key executives. Get a clear view of the benefit. Find the point of difference. Then write the boilerplate one sentence at a time, so each sentence can stand on its own and supply a reporter with language worth reusing.
“We don't start writing a whole boilerplate. We write one sentence at a time.”Kimberly Capwell, founder and CEO
This sounds almost comically modest beside the machinery of modern marketing. Yet it exposes the first thing that often fails in technical communication: the message is assembled from everything the company knows instead of the one thing the audience needs to grasp. More channels merely distribute the confusion faster.
Capwell's correction is positioning before publicity. Decide what category the company belongs in, what it changes and what evidence supports the claim. Only then choose the channels. That sequence can be copied: interview the people closest to the product; isolate a defensible benefit; draft one independent sentence; test whether a stranger can repeat it; build the campaign outward from there.
A radio instinct in a regulated market
Capwell grew up in South Dakota and started as a country-music radio DJ. The biographical detail is amusing until it becomes explanatory. Radio teaches ruthless clarity. A listener may be driving, cooking or disappearing down the dial. You have seconds to establish why the next thing matters.
Healthcare communication adds a complication: the memorable line must also survive evidence, regulation and expert scrutiny. Capwell found a niche in that tension. The firm's published portfolio includes work connected to Dexcom's continuous glucose monitoring, Ivantis's Hydrus Microstent, Eyenuk's AI eye-screening system, Prolacta Bioscience's human-milk nutrition products and Edwards Lifesciences' heart-valve business. These are not impulse purchases. They need trust before they need buzz.
- Fundraising
- Clinical evidence
- FDA milestone
- Market launch
- Acquisition or IPO
That long runway explains the seven-year average engagement Capwell reports. A generalist agency can learn a launch. A specialist that stays through multiple trials, regulatory turns and leadership changes accumulates the client's institutional memory. The relationship becomes expensive to replace, not because the contract traps anyone, but because context does.
The first thing Capwell discarded
Before remote work became an employee benefit, Capwell presented it as an operating model. Its founder had left what the company describes as the big, brick-and-mortar agency track. The conventional pyramid carried visible overhead and often put junior staff between senior counsel and the client. Capwell's answer was virtual, small and senior-led.
The trade is real. A seven-client ceiling gives up the revenue of the eighth account. It also turns attention into a promise the agency can plausibly keep. Public pricing is not listed; the more revealing cost is opportunity. Capwell is choosing depth over throughput every time it leaves that eighth seat empty.
The bet held through a difficult year. In 2020, when many agencies faced a pullback, Capwell reported 23 percent growth, its fourth straight year of double-digit gains. It added healthcare clients and leaned on relationships already measured in years. In 2022, Bulldog Reporter named it Best Small Agency of the Year. The 2026 awards gave Capwell bronze honors for Best Boutique Agency and Most AI-Ready Agency.
Position the difference
Name the category, the benefit and the proof before chasing attention.
Match the milestone
Fundraising, clinical data and an FDA decision each require a different story and audience.
Keep the drumbeat
Use earned coverage, executive visibility and owned content to stay legible between big announcements.
Measure the understanding
Track whether the market names, cites and differentiates the brand, not merely whether it saw it.
When search stops sending the click
The firm's newest service is Capwell Total Visibility, an attempt to carry its positioning discipline into generative search. Capwell says it audits how a life-sciences brand appears across systems such as ChatGPT, Claude, Perplexity and Google's AI Overviews, then provides a dashboard tracking whether the company is named and differentiated in generated answers.
The channel is new; the premise is old. If a company's evidence and identity are scattered, a reporter may misunderstand it. An answer engine may do the same at larger speed. Capwell's response is to structure the digital footprint and place the brand in authoritative third-party contexts that machines can recognize. The firm is effectively treating earned media as both human persuasion and machine-readable reputation.
A small team can borrow the method without hiring an agency: write the one sentence first, tie every announcement to evidence, keep a steady record between milestones and audit how outsiders describe the company. It works when the underlying claim is specific and supportable. It weakens when the product has no meaningful difference, the evidence is thin or leadership wants attention before it can agree on what is true.
Small is not the same as narrow
Capwell's archive ranges beyond medtech. It includes consumer campaigns and work associated with Coca-Cola, Guinness, Dr. Teal's and WHAM-O. But the modern firm's sharper identity is healthcare: a place where scientific complexity, patient stakes and long financing cycles reward accumulated judgment.
Its customers are founders and executive teams who need the market to understand a difficult thing before the company runs out of time, money or patience. The competitors include specialist firms such as LifeSci Communications and Burns McClellan, large health practices inside global networks, and the in-house hire who promises to do it all. Capwell's distinction is not that it offers a channel nobody else has. It is the combination of a capped roster, senior counsel, regulated-market fluency and the willingness to stay.
The charming paradox is that a communications firm has made restraint part of its message. Seven seats. One sentence at a time. A decade and a half of choosing what not to add. In a business devoted to generating more attention, Capwell's most persuasive act may be limiting its own.